CVS Health Corporation (CVS) Guidance & Earnings Results

On 2026-08-05 CVS Health Corporation raised guidance: "GAAP diluted EPS raised to $6.84-$7.04; Adjusted EPS to $7.90-$8.10; cash flow from operations to at least…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CVSCVS Health CorporationFollow CVS — free

Healthcare Plans · Healthcare

—

Price chart with a free account

Market cap: 119.5B
P/E TTM: 24.6
Dividend yield: 2.8%
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	GAAP diluted EPS raised to $6.84-$7.04; Adjusted EPS to $7.90-$8.10; cash flow from operations to at least $11.5B · full year
6 May 26	Raised	GAAP diluted EPS raised from $5.94-$6.14 to $6.24-$6.44; Adjusted EPS raised from $7.00-$7.20 to $7.30-$7.50; Cash flow from operations raised from at least $9.0B to at least $9.5B · full year
29 Oct 25	Raised	Adjusted EPS guidance raised to $6.55-$6.65 from $6.30-$6.40; cash flow from operations guidance raised to $7.5B-$8.0B · full year
31 Jul 25	Mixed	FY25 GAAP diluted EPS $3.84-3.94 (from $4.23-4.43); FY25 Adjusted EPS $6.30-6.40 (from $6.00-6.20); FY25 cash flow from operations at least $7.5B (from ~$7.0B) · full year

CVS Health Corporation — questions

What guidance did CVS Health Corporation give?: On 2026-08-05: "GAAP diluted EPS raised to $6.84-$7.04; Adjusted EPS to $7.90-$8.10; cash flow from operations to at least $11.5B"
When does CVS Health Corporation report earnings?: CVS Health Corporation's next earnings report is expected on 2026-11-04.

Every figure on this page comes from CVS Health Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.